1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Aptabio Therapeutics, Inc.

Aptabio Therapeutics, Inc.

KKRX:293780
6,240.00
KRW
-500.00
(-7.42%)
-541.63EPS
129.51BMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
33.2
105.76
51.43
15.49
14.9
2.17
14.28
142.78
137.32
173.14
Basic EPS, GAAP
-3,443
-295.5
-318
-178
-712
-474
-532
-1,248
-607
-541.63
Free Cash Flow per Basic Share
-199.09
-129.2
-491.88
-266.25
-603.92
-359.8
-629.08
-526.76
-569.45
-633.95
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-1,453.59
843.98
3,453.27
3,246.45
2,778.15
2,348.53
2,728.6
2,016.16
1,679.56
1,502.15
Tangible Book Value per Share
-1,453.68
843.6
3,452.67
3,244.32
2,776.25
2,346.83
2,725.86
2,014.69
1,642.07
1,464.89
Basic Weighted Avg Shares
9
14
20
22
15
22
23
24
27
27
Sales/Revenue/Turnover
300
1,454
1,019
341
224
48
324
3,361
3,698
4,753
Operating Margin (%)
-712.17
-231.21
-702.06
-1,778.3
-5,081.88
-19,661.23
-5,055.61
-560.98
-420.14
-394.74
Depreciation Expense
6
10
75
243
344
485
539
531
481
435
Net Income, GAAP
-31,123
-4,063
-6,298
-3,919
-10,689
-10,565
-12,062
-29,378
-16,346
-14,869
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-10,372.02
-279.42
-618.31
-1,149.08
-4,778.8
-21,849.25
-3,724.24
-874.09
-442.04
-312.83
Working Capital
-12,283
18,771
46,036
42,944
22,989
19,379
56,656
15,395
15,636
13,684
LT Debt
- -
- -
61
35
47
256
13,803
122
31
11
Total Equity
-31,538
18,312
75,155
72,040
61,665
52,370
61,363
54,197
47,185
42,200
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
-13.48
-5.32
-15.99
-18.53
-21.31
-51.07
-32.25
-33.15

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
4,391
4,644
4,902
LT Borrowings
- -
- -
- -
LT Finance Leases
31
15
11
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
28
28
28
Market Capitalization
262,673
193,844
129,511

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
25,351
16,559
22,579
Cash, Cash Equivalents & STI
17,190
8,840
15,725
Accounts Receivable, Net
591
757
681
Inventories
613
726
598
Total Current Liabilities
9,715
9,638
8,895
Payables & Accruals
- -
- -
- -
ST Debt
4,391
4,644
4,902
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-7.38%
-12.94%
Free Cash Flow
- -
26.32%
23.67%
Net Income, GAAP
- -
57%
-44.36%
Sales/Revenue/Turnover
- -
280.96%
10.02%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
637
1,120
859
744
3,361
2025
383
1,122
1,192
1,001
3,698
2026
957
1,603
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-170
-301
-325
-404.3
-1,248
2025
-101
-157
-114.13
-240.15
-607
2026
-229.41
40
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Su-Jin Lee
Full Time Employees
45
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Heungdeok IT Valley, 13 Yongin-si GY South Korea 16954
IPO Date
Jun 12, 2019
Website
aptabio.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
AptaBio Therapeutics Inc. (293780.KQ) develops platform-based therapeutics targeting intractable diseases, including selective inhibitors of NADPH oxidase (NOX) family enzymes and aptamer-drug conjugates for anti-cancer applications; its research platforms encompass oxidative stress modulation for diabetic complications such as nephropathy and retinopathy, vascular and neurodegenerative diseases, nonalcoholic steatohepatitis, and intractable cancers including pancreatic, bladder, and liver types, alongside cancer-associated fibroblast control and aptamer-drug conjugate technologies; the company commercializes transfection reagents such as Lipofector-Q, Lipofector-EXT, Lipofector-2000, Lipofector-EZ, and Lipofector-pMAX for DNA/RNA delivery into eukaryotic cells, with sales primarily from reagent and product offerings in South Korea. Founded in 2009 and headquartered in Yongin-si, Gyeonggi-do, South Korea, AptaBio operates in the biopharmaceutical sector, focusing on first-in-class new drugs for inflammation, fibrosis, diabetic complications, and oncology, partnering with universities, hospitals, contract research organizations, and contract manufacturing organizations. In 2023, the company secured approximately KRW 50 billion in funding to support its pipeline advancement; key candidates include APX-115 (NOX inhibitor, Phase unspecified for acute kidney injury and oxidative stress), Isuzinaxib (Phase 2 for diabetic nephropathies), APX-311 (Phase 2 for nonalcoholic steatohepatitis), APX-1004 (Phase 1 for diabetic retinopathy), and APX-343A (Phase 1 for advanced solid tumors), reflecting ongoing clinical progress and revenue growth from KRW 48 million in 2022 to KRW 3.36 billion in 2024 driven by new business and reagent sales.